Angelica Guardia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Angelica Guardia has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Tong Shi
Department of Biomedical Engineering, Wayne State University, Detroit, MI 48201, USA
2 shared publications- Weiping Ren
Department of Orthopedics, Henry Ford Providence Southfield Hospital, Southfield, MI 48075, USA
2 shared publications Bin Wu
Department of Orthopedics Providence Hospital Southfield Michigan USA
1 shared publicationDavid Markel
Department of Biomedical Engineering Wayne State University Detroit Michigan USA
1 shared publicationEmily J Ren
Department of Orthopedics, Detroit Medical Center, Detroit, MI 48201, USA
1 shared publicationPaula Dietz
Department of Orthopedics Providence Hospital Southfield Michigan USA
1 shared publication
Latest Publications
- Open Access
- 2 June 2021
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 2 (14) , 4652-4658
A slow and sustained release of methotrexate (MTX) from a new polymeric dicalcium phosphate dehydrate cement (P-DCPD)
A novel and injectable polymeric dicalcium phosphate dihydrate (P-DCPD) was developed by the reaction of acidic CPP gel with alkali TTCP that is completely different from classical DCPD. P-DCPD is mechanically strong and has excellent cohesion.
- 2 June 2021
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 2 (14) , 4652-4658
Open AccessA slow and sustained release of methotrexate (MTX) from a new polymeric dicalcium phosphate dehydrate cement (P-DCPD)
A novel and injectable polymeric dicalcium phosphate dihydrate (P-DCPD) was developed by the reaction of acidic CPP gel with alkali TTCP that is completely different from classical DCPD. P-DCPD is mechanically strong and has excellent cohesion.
- 31 December 2020
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 39 (11) , 2446-2454
Properties of erythromycin‐loaded polymeric dicalcium phosphate dehydrate bone graft substitute
A self‐setting, injectable polymeric dicalcium phosphate dehydrate bone graft substitute that is mechanically strong and has excellent cohesion was developed. We assessed the performance of erythromycin‐loaded polymeric dicalcium phosphate dehydrate cement. Its properties include drug release, growth inhibition against Staphylococcus aureus and biocompatibility with osteoblastic MC3T3 cells. The impact of erythromycin loading on cement injectability, setting time, and mechanical strength were also evaluated. A sustained, low burst release of erythromycin was observed. Eluents collected from erythromycin‐loaded cement showed a considerable zone of inhibition for up to 28 days. Direct contact of erythromycin‐loaded cement discs with agar plate showed a similarly sizable zone of inhibition for up to 22 days. Degraded ceramic residues had strong zones of inhibition as well. While the erythromycin‐loaded cement was injectable, a notable delay of the setting time was observed (49.2 ± 6.8 min) as compared with control (drug‐free cement, 12.2 ± 2.6 min). A slight increase in compressive strength (60.83 ± 6.28 MPa) was observed in erythromycin‐loaded cement as compared with control (59.41 ± 6.48 MPa). Erythromycin‐loaded cement was biocompatible although reduced cell growth was observed in the presence of the cement eluent. We propose that the bactericidal efficacy of erythromycin‐loaded cement was caused by the combined effects of erythromycin released and exposed on the contact surface of degrading ceramics. Our data may elucidate the future application of polymeric dicalcium phosphate dehydrate bone graft substitute for the treatment of orthopedic infections and opportunities to use other antibiotics and applications considering its comparable handling and mechanical strength to poly (methyl methacrylate) cements.
- 31 December 2020
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 39 (11) , 2446-2454
Properties of erythromycin‐loaded polymeric dicalcium phosphate dehydrate bone graft substitute
A self‐setting, injectable polymeric dicalcium phosphate dehydrate bone graft substitute that is mechanically strong and has excellent cohesion was developed. We assessed the performance of erythromycin‐loaded polymeric dicalcium phosphate dehydrate cement. Its properties include drug release, growth inhibition against Staphylococcus aureus and biocompatibility with osteoblastic MC3T3 cells. The impact of erythromycin loading on cement injectability, setting time, and mechanical strength were also evaluated. A sustained, low burst release of erythromycin was observed. Eluents collected from erythromycin‐loaded cement showed a considerable zone of inhibition for up to 28 days. Direct contact of erythromycin‐loaded cement discs with agar plate showed a similarly sizable zone of inhibition for up to 22 days. Degraded ceramic residues had strong zones of inhibition as well. While the erythromycin‐loaded cement was injectable, a notable delay of the setting time was observed (49.2 ± 6.8 min) as compared with control (drug‐free cement, 12.2 ± 2.6 min). A slight increase in compressive strength (60.83 ± 6.28 MPa) was observed in erythromycin‐loaded cement as compared with control (59.41 ± 6.48 MPa). Erythromycin‐loaded cement was biocompatible although reduced cell growth was observed in the presence of the cement eluent. We propose that the bactericidal efficacy of erythromycin‐loaded cement was caused by the combined effects of erythromycin released and exposed on the contact surface of degrading ceramics. Our data may elucidate the future application of polymeric dicalcium phosphate dehydrate bone graft substitute for the treatment of orthopedic infections and opportunities to use other antibiotics and applications considering its comparable handling and mechanical strength to poly (methyl methacrylate) cements.